August 25th 2025
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
August 19th 2025
The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications
August 15th 2025
Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised
August 14th 2025
Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond
August 13th 2025
New financing will support the company's lead retinitis pigmentosa programme, among other projects
Sandoz will license Lupin's ranibizumab biosimilar in Europe, other select regions
Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries
German case study illustrates systemic presentation of tubulointerstitial nephritis and uveitis
An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation
NICE announces UK approval of idebenone for treatment of Leber hereditary optic neuropathy
In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment
A realistic view of diabetes remission: GLP-1 therapies and the future of diabetic retinopathy
GLP-1 therapies could impact long-term outcomes in diabetic retinopathy
Managing and monitoring the global burden of retinoblastoma
Enhanced screenings and a unified registry could save vision and lives
Opus Genetics, Global RDH12 Alliance announce new collaboration
The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight
Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition
The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening
Exonate announces CLEAR-DE trial for EXN407
Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy
Biomarkers of microvascular retinal perfusion indicating coronary heart disease
Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography
Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI
According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”
Fungal infection and vision impact in patients with diabetic eye disease
Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests
New microbial strain produces high yields of lutein for AMD, cataract prevention
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity
FDA agrees to expand Atsena's gene therapy trial for XLRS treatment
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration
The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD
Long-duration spaceflight tests the limits of telemedicine
In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained
Patients with high genetic risk of AMD should avoid instant coffee, investigators say
Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval
With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.
The significance of FLIO in diabetic eye disease
Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers
How remote retinal imaging raises the bar across service, research and education
Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium
Differentiating physiology from pathology in the paediatric vitreous
Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture
Imaging the ellipsoid zone line could change the global approach to clinical trials
Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium
Neeraj Dhaun, MD, PhD, says advances in OCT tech may positively impact patients with chronic kidney disease
Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium
Gereon Hüttmann, PhD, introduces holographic OCT to a new audience
The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium
Ruth Hogg, PhD, says NICOLA data emphasise the value of multicolor images
Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium
Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)
Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.